July 3 (Reuters) - Anavex Life Sciences Corp AVXL.O :
* ANAVEX LIFE SCIENCES RECEIVES APPROVAL TO INITIATE PHASE 2B/3 CLINICAL TRIAL OF ANAVEX®2-73 FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE
* ANAVEX LIFE SCIENCES RECEIVES APPROVAL TO INITIATE PHASE 2B/3 CLINICAL TRIAL OF ANAVEX®2-73 FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE
* ANAVEX LIFE - RECEIVED APPROVAL BY AUSTRALIAN HUMAN RESEARCH ETHICS COMMITTEE TO INITIATE PHASE 2B/3 48-WEEK SAFETY AND EFFICACY TRIAL OF ANAVEX®2-73